Cancer medicines
Carfilzomib
Carfilzomib
A proteasome inhibitor used in selected relapsed/refractory myeloma.
Sources checked · Introductory guide
On this page
How it works
It inhibits protein-degrading proteasomes to promote cancer cell death.[3]
Where it is used
Used alone or with dexamethasone and other medicines in selected previously treated myeloma.[1]
Key safety points
Review heart, blood pressure and kidneys. Report new breathlessness, chest pain, swelling or low urine immediately; follow individualized fluid instructions.[2]
Questions for your care team
- What cardiac, kidney, fluid and postinfusion contact plan applies?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Carfilzomib (opens in a new tab)
- MedlinePlus · Carfilzomib (opens in a new tab)
- NCI Drug Dictionary · Carfilzomib (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.